Corundum Group Inc. Grows Holdings in Pfizer Inc. $PFE

Corundum Group Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 3.0% during the second quarter, Holdings Channel reports. The institutional investor owned 32,175 shares of the biopharmaceutical company’s stock after acquiring an additional 934 shares during the quarter. Corundum Group Inc.’s holdings in Pfizer were worth $780,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth about $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter worth about $28,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth about $28,000. WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $35,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PFE. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Price Performance

NYSE PFE opened at $27.37 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The firm has a market capitalization of $155.59 billion, a P/E ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average price of $24.67 and a 200-day moving average price of $24.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.